Valuation: Artivion, Inc.

Market Cap 1.09B 951M 878M 819M 1.54B 103B 1.57B 10.53B 4.09B 50.71B 4.08B 3.99B 177B P/E 2026 *
267x
P/E 2027 * 54.9x
Enterprise Value 1.09B 951M 878M 819M 1.54B 103B 1.57B 10.53B 4.09B 50.71B 4.08B 3.99B 177B EV / Sales 2026 *
2.24x
EV / Sales 2027 * 2.01x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day-0.29%
1 week+8.15%
Current month+0.79%
1 month+6.25%
3 months-36.84%
6 months-51.37%
Current year-50.96%
1 week 20.73
Extreme 20.73
24.04
1 month 19.82
Extreme 19.82
24.04
Current year 19.16
Extreme 19.16
46.84
1 year 19.16
Extreme 19.16
48.25
3 years 12.16
Extreme 12.1582
48.25
5 years 9.64
Extreme 9.64
48.25
10 years 9.64
Extreme 9.64
48.25
Manager TitleAgeSince
Chief Executive Officer 59 2014-09-01
Director of Finance/CFO 53 2023-12-03
Chief Tech/Sci/R&D Officer 56 2023-05-31
Director TitleAgeSince
Director/Board Member 71 2003-11-30
Director/Board Member 66 2003-11-30
Director/Board Member 61 2012-04-30
Date Insider Type Main position Quantity % Market Cap.
Jun. 10Fiscal year

General Counsel

132,003 0.2719%
Jun. 01Others

Director

-12,650 0.0261%
May. 31Other

General Counsel

104,260 0.2148%
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+8.15%-28.09%+30.10% 1.09B
-1.79%+0.56%-33.06%-16.49% 161B
-2.61%-2.16%-9.50%-10.45% 104B
+0.55%+1.01%-5.30%+47.56% 54.8B
+0.56%-3.80%+53.05%+53.64% 53.31B
-2.05%+5.61%-11.76%-42.43% 42.76B
-0.90%+10.98% - - 33.49B
-2.78%-1.28%-22.06%-47.06% 27B
+1.28%+6.42%+63.61%-6.40% 25.06B
-1.55%+3.35%-12.57%-6.65% 20.78B
Average -0.99%+5.92%-0.63%+0.20% 52.34B
Weighted average by Cap. -1.35%+4.66%-7.31%-3.33%

Financials

2026 *2027 *
Net sales 486M 426M 393M 366M 690M 45.97B 703M 4.71B 1.83B 22.69B 1.83B 1.79B 79.03B 540M 472M 436M 407M 767M 51.04B 780M 5.23B 2.03B 25.19B 2.03B 1.98B 87.74B
Net income 4.4M 3.85M 3.56M 3.32M 6.25M 416M 6.36M 42.64M 16.56M 205M 16.53M 16.16M 715M 22.59M 19.77M 18.25M 17.02M 32.08M 2.14B 32.65M 219M 84.99M 1.05B 84.86M 82.96M 3.67B
Net Debt - -
Logo Artivion, Inc.
Artivion, Inc. is a medical device company focused on developing solutions that address cardiac and vascular surgeons in treating patients with aortic diseases. The Company operates through two segments, which include Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, On-X products, and other products. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, On-X mechanical heart valves and related surgical products, surgical sealants, and implantable cardiac and vascular human tissues. Its aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Its surgical sealants include BioGlue Surgical Adhesive products. It is engaged in the endovascular repair of aortic arch disease and the developer of the NEXUS Aortic Arch System.
Employees
1,800
Date Price Change Volume
26-06-30 $22.30 -0.40% 554,297
26-06-29 $22.39 -5.17% 1,017,308
26-06-26 $23.61 +4.19% 2,614,166
26-06-25 $22.66 +2.86% 1,161,724
26-06-24 $22.03 +6.53% 915,175
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
22.39USD
Average target price
42.00USD
Spread / Average Target
+87.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AORT Stock